Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: pregelatinised potato starch; ascorbyl palmitate; magnesium stearate; lactose monohydrate; lactose - ? short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women. ? second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, <> (tibolone tablets) should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at that moment (including cardiovascular disease and breast cancer, see clinical trials and precautions). <> (tibolone tablets) should only be continued for as long as the benefit outweighs the risks.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; hypromellose; sorbitan stearate; magnesium stearate; titanium dioxide; purified talc; triacetin; iron oxide yellow - tadalafil sandoz is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - inglés - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; hypromellose; sorbitan stearate; magnesium stearate; titanium dioxide; purified talc; triacetin; iron oxide yellow - apo-tadalafil is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - inglés - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; hypromellose; sorbitan stearate; magnesium stearate; titanium dioxide; purified talc; triacetin; iron oxide yellow - tadalaccord is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - inglés - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; sodium lauryl sulfate; purified talc; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; titanium dioxide; hypromellose; iron oxide yellow; triacetin - ciavor is indicated for the treatment of: erectile dysfunction (ed) in adult males; moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: microcrystalline cellulose; polyethylene oxide; magnesium stearate - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

Australia - inglés - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: magnesium stearate; polyethylene oxide; microcrystalline cellulose - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

Australia - inglés - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: polyethylene oxide; magnesium stearate; microcrystalline cellulose - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

Australia - inglés - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: quinoline yellow; purified talc; polyethylene oxide; cochineal; microcrystalline cellulose; magnesium stearate; hyprolose; butylated hydroxytoluene; macrogol 400; titanium dioxide; iron oxide black; hypromellose; colloidal anhydrous silica - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

Australia - inglés - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tadalafil, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; colloidal anhydrous silica; povidone; poloxamer; croscarmellose sodium; sodium lauryl sulfate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - tadalafil alphapharm is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males